Melanin synthesis pathway enzyme

The term "melanin synthesis pathway enzymes" collectively refers to the key enzymes responsible for the biosynthesis of melanin, a pigment found in skin, hair, and eyes. The most critical among these is **tyrosinase**, a copper-containing enzyme that catalyzes the first and rate-limiting steps: the conversion of tyrosine to L-DOPA and then dopaquinone[1][6][7]. Additional important enzymes include **tyrosinase-related protein 1 (TYRP1)** and **tyrosinase-related protein 2 (TYRP2; also called DOPAchrome tautomerase)**, which further process melanin intermediates along eumelanin and pheomelanin branches[3][5]. These enzymes are primarily expressed in **melanocytes** and are regulated at both the transcriptional level (primarily by the transcription factor MITF) and via multiple signaling pathways, including cAMP, MAPK, and PI3K/AKT[3][4]. Disorders in the function of these enzymes are linked to pigmentation abnormalities and diseases such as albinism, vitiligo, hyperpigmentation, and melanoma[1][6]. Many topical or systemic drugs (e.g., hydroquinone, kojic acid, proton pump inhibitors) act as inhibitors of tyrosinase or related enzymes, targeting these pathways for cosmetic or therapeutic purposes[2][8]. **Note:** "Melanin synthesis pathway enzyme" is a collective rather than a specific canonical target. Whenever possible, refer to individual enzymes—such as **tyrosinase (TYR)**, **tyrosinase-related protein 1 (TYRP1)**, and **tyrosinase-related protein 2 (TYRP2)**—for greater specificity and standardized nomenclature. Thus, **is_incorrect: true**, as it is not a singular, specific target. Key sources: [1][3][6][7][8][4][2][5]

Other names

Melanogenesis enzymeEnzyme of melanin synthesisMelanin biosynthetic pathway enzyme

Enzyme inhibition (e.g., direct tyrosinase inhibition) - Interference with copper ion delivery (inhibition of ATP7A affecting tyrosinase) - Regulation of transcription (e.g., siRNA against MITF, affecting enzyme expression) - Indirect inhibition via signal pathway modulation (e.g., interfering with cAMP, MAPK, or PI3K/AKT pathways)